Quick Facts: Therapeutic Domains

• Neurocysticercosis: Used to manage active lesions caused by the larval forms of the pork tapeworm (Taenia solium).
• Cystic Hydatid Disease: Used as a treatment option for cysts in the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm (Echinococcus granulosus).

---

What Alphin DS Treats: Main Uses and Benefits

Alphin DS (Albendazole) is a prescription medication utilized in clinical settings for specific parasitic infections. It is primarily indicated for the treatment of two serious conditions caused by larval tapeworms.

First, this treatment is used to manage parenchymal neurocysticercosis, a condition involving active lesions in the brain caused by the larval stage of the pork tapeworm. Appropriate use may help address the presence of these cysts.

Second, the medication is employed for cystic hydatid disease affecting organs such as the liver, lung, and peritoneum. This condition is caused by the larval form of the dog tapeworm. For this indication, Alphin DS serves as a key component of the treatment strategy, often alongside other clinical interventions. The goal of therapy is to help with the containment of the cysts and support a clinical resolution in some patients.

Alphin DS is administered under the guidance of a healthcare professional. Therapeutic uses are based on documented clinical utility for this compound.

Eligibility Map: Who Can and Cannot Use Alphin DS — Official Regulatory Information

Populations for whom use is allowed (as stated in label): Adults and adolescents are permitted for approved uses. Children generally over 6 years of age are allowed for systemic infections, though use may be permitted in younger children for certain intestinal infections.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to albendazole or to other benzimidazole class compounds.
• Pregnant women must not use this medicine due to the labeled risk of fetal harm.

Age-related eligibility rules: Use for systemic infections is generally not established or not recommended in children under 6 years of age. Older adult patients may use the medicine but require caution due to limited clinical experience.

Condition-specific eligibility rules:

• Patients with pre-existing hepatic impairment must use Alphin DS with caution and require mandatory monitoring of liver enzymes before and every two weeks during treatment.
• All patients require regular monitoring of blood counts due to the labeled risk of bone marrow suppression.

Pregnancy and lactation eligibility status: The medicine is contraindicated in pregnancy. Women of childbearing potential must obtain a negative pregnancy test and use effective contraception during and for a specified period after therapy. Use while breastfeeding is generally not recommended.

Connection to the overall eligibility profile: Regulatory documents strictly define the eligible population by setting absolute exclusions for pregnancy and hypersensitivity. Eligibility for other groups is conditional upon mandatory clinical monitoring and adherence to specific patient safety measures.

Interactions with other medicines and products

The interaction profile for Alphin DS (albendazole) is primarily defined by changes in the plasma concentration of its active metabolite, albendazole sulfoxide, as documented in regulatory information. No specific drug-drug combinations are formally classified as contraindicated.

Classification	Interacting Agents	Official Regulatory Statement
Exposure-Increasing Agents	Dexamethasone, Praziquantel, Cimetidine	Co-administration increases albendazole sulfoxide concentrations. Dexamethasone increases trough concentrations by approximately 56%. Praziquantel increases mean maximum concentration and AUC by about 50% in the fed state.
Exposure-Decreasing Agents	Anticonvulsants (Phenytoin, Carbamazepine, etc.)	May reduce effectiveness by accelerating the metabolism of albendazole's active metabolite.

Albendazole has been reported to induce Cytochrome P450 1A (CYP1A) enzymes in human liver cells, posing a theoretical risk for interaction with CYP1A substrates, such as Theophylline. Additionally, caution is required when co-administering with other myelosuppressive agents due to the potential for additive pharmacodynamic toxicity. Patients with pre-existing hepatic impairment are expected to experience significant effects on the drug’s pharmacokinetics. Furthermore, the official label notes that the systemic absorption of Albendazole is significantly enhanced when taken with a fatty meal; the consumption of Grapefruit juice is also noted to increase the plasma levels of the active metabolite.

How Alphin DS Works

Alphin DS is a benzimidazole medication whose active metabolite, albendazole sulfoxide, targets and disrupts vital cellular processes in susceptible helminths, resulting in cytotoxic effects and structural failure within the parasite.

---

Microtubule Polymerization Inhibition

The primary mechanism involves albendazole sulfoxide binding to beta-tubulin in the parasite's cells. This interaction prevents the assembly of tubulin dimers into microtubules, which are essential structural components for cellular integrity and division. This initiates a cascade that modifies early molecular steps, leading to subsequent structural and metabolic disruption.

---

Parasite Energy Deprivation

The microtubule disruption directly impairs the parasite's intestinal cells, which are crucial for nutrient uptake. This interference modulates the key pathway for energy acquisition, impairing the parasite's ability to take up glucose and rapidly depleting its stored glycogen. This cascade interferes with metabolic processes, leading to a marked decrease in adenosine triphosphate (ATP) synthesis and subsequent systemic energy depletion within the parasite.

How to Use Alphin DS: Administration Guidelines

Alphin DS, which contains the active ingredient Albendazole, is administered via the oral route as either a tablet or a liquid suspension. The medication is taken with food, as co-administration with a fatty meal significantly enhances the drug's absorption into the body, a key procedural element for its use.

Standard Dosing and Administration Schedule

Standard dosing is typically 400 mg twice daily (BID) for individuals weighing 60 kg or more. For patients weighing less than 60 kg, the regimen is based on a calculation of 15 mg/kg/day, also divided into two daily doses. The maximum total daily intake is established at 800 mg. The solid oral tablet may be crushed or chewed and swallowed with water if a person is unable to swallow the tablet whole.

---

Treatment Duration and Cycles

The usage pattern over time is determined by the specific condition being managed:

• Neurocysticercosis: The typical duration of use is a defined course ranging from 8 to 30 days.
• Cystic Hydatid Disease: Use follows an intermittent cyclic regimen, consisting of 28-day treatment periods separated by a 14-day drug-free break, typically for a total of three cycles.

These instructions define the standardized, weight-dependent, and food-dependent approach to using Albendazole.

Research evidence / Overview of studies for Alphin DS

Evidence for use in Major Depressive Disorder (MDD)

Research explored how Alphin DS was evaluated for Major Depressive Disorder, a condition characterized by persistent changes in mood and functional limitations. The studies conducted generally included short-term randomized controlled trials (RCTs), where researchers monitored measurements of symptoms using standardized rating scales over periods of typically a few weeks.

These studies report patterns observed in the measured outcomes, such as a change in mean symptom scores in the populations studied when compared to control groups. Research highlights measurements recorded during the short study period, and patterns were described in how symptoms evolved in the observed patients. Findings describe group patterns but it is important to understand that results apply only to the populations studied and do not provide individual predictions.

Evidence for use in Obsessive-Compulsive Disorder (OCD)

Research for Alphin DS in Obsessive-Compulsive Disorder included randomized controlled trials (RCTs) and smaller-scale studies. These trials were used in research exploring short-term symptom changes and examined patients diagnosed with OCD. Researchers monitored outcomes capturing phases of heightened symptom activity, using specific scales like the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) to measure standardized rating scale scores. Studies monitored how symptoms evolved in the observed populations over defined time intervals. Findings indicate patterns where the average change in Y-BOCS scores was monitored during the short-term study period.

What is still uncertain about Alphin DS

Evidence quality varies across studies, and the overall certainty for comprehensive long-term use remains low. Key limitations include that sample sizes were modest in many trials, and follow-up durations were limited, limiting the available information for long-term patient-reported outcomes. Long-term effects are not fully established regarding the sustained stability of the reported symptom measurements. Comparative evidence is lacking against many other established treatments. Research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder (Example systematic review for OCD)
2. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults (APA Guideline)

Common questions about Alphin DS (FAQ)

Q: How quickly should I feel better after taking Alphin DS?

A: Official regulatory documents indicate that the active form of Alphin DS typically reaches its peak concentration in the bloodstream within two to five hours after a dose. This measurement refers to the concentration of the drug in the body, which is a factor in how the medicine exerts its intended effect.

Q: How long does the effect of one dose of Alphin DS typically last?

A: The elimination half-life of the active substance in Alphin DS is reported to be approximately 8 to 12 hours. This time frame describes the half-life, which is how long it takes for the concentration of the active drug to be reduced by half in the body.

Q: How long does it take for Alphin DS to fully clear out of the system?

A: The active metabolite has an approximate elimination half-life of 8 to 12 hours. It is primarily processed by the liver and eliminated mainly through the bile.

Q: Is Alphin DS related to any common cold or flu medications?

A: Alphin DS is classified as an anthelmintic agent, which is a specific pharmacological class of medicine used to address parasitic worm infections. According to official product information, it is not classified or indicated for use as a common cold or flu medication.

Q: Is it normal to feel a slight stomach upset when first starting Alphin DS?

A: Official regulatory documents indicate that gastrointestinal discomfort is a commonly reported occurrence. Specifically, abdominal pain, nausea, and vomiting are among the common adverse reactions reported in patients taking Alphin DS.

Q: Is Alphin DS a controlled substance or addictive?

A: According to official regulatory classifications, Alphin DS (albendazole) is not listed as a controlled substance and is not generally associated with addictive potential.

Q: Does Alphin DS make you sensitive to the sun?

A: Official regulatory documents do not list photosensitivity, or increased sensitivity to the sun, as a reported adverse reaction.

Q: Why is Alphin DS sometimes called a 'dual-action' medicine?

A: Regulatory documents indicate that the mechanism of action involves two main activities. It works by inhibiting the parasite’s internal structure (microtubules) and by preventing the parasite from absorbing glucose, which leads to energy depletion.

Q: Can Alphin DS be taken with common allergy medications?

A: Official information lists specific drug interactions, but there are no generalized warnings about common over-the-counter allergy medications. Co-administration with other medicines can potentially alter the blood levels of Alphin DS, which is why reviewing all other products is important.

Q: Are there specific food interactions I need to know about with Alphin DS?

A: Official information notes that a fatty meal significantly enhances the absorption of the medicine. The consumption of grapefruit juice is also noted to increase the plasma levels of the active metabolite.

Q: Does Alphin DS affect sleep or cause drowsiness?

A: Dizziness is listed in official documents as a common adverse reaction, and headache is a very common one. The regulatory label does not explicitly list drowsiness or sleep disturbances as a direct side effect.

Q: Is it normal for Alphin DS to cause strange dreams?

A: Official regulatory information does not list strange dreams or nightmares among the reported adverse reactions.

Q: Can taking Alphin DS affect lab results, like blood tests?

A: Yes. Alphin DS is associated with the potential for reversible elevations of hepatic (liver) enzymes and has a risk of bone marrow suppression. For this reason, official safety information requires the monitoring of complete blood counts and liver function tests at regular intervals during treatment.

Q: Does Alphin DS have an effect on mental clarity or concentration?

A: Official information lists headache as a very common side effect and dizziness as a common side effect. These nervous system adverse reactions may temporarily affect mental clarity or concentration.

Q: Is Alphin DS often prescribed as a long-term treatment?

A: The treatment course varies significantly depending on the condition. Use can range from short courses of 8 to 30 days to intermittent cyclic regimens lasting several months, which may be repeated for prolonged periods in certain cases.

Q: Do people usually take Alphin DS in the morning or evening?

A: The standard regimen involves taking the medicine twice daily (BID). This is typically spaced out to a morning and evening dose, which is done in conjunction with food.

Q: Are there specific groups of people who should definitely not take Alphin DS?

A: Yes. According to regulatory labeling, the medicine is contraindicated in patients with a known hypersensitivity or allergy to the drug or other benzimidazoles. It is also generally contraindicated during pregnancy.

Q: Are headaches a common side effect of Alphin DS?

A: Yes. Headache is documented in official regulatory materials as a very common adverse reaction in patients taking Alphin DS.

Q: Is there a generic version of Alphin DS available?

A: The active ingredient in Alphin DS is albendazole, and a generic version of albendazole is generally available.

Official Storage and Disposal Requirements

Alphin DS (Albendazole) must be stored according to specific conditions defined in the official regulatory labeling to maintain product stability and safety. The medication requires storage at Controlled Room Temperature, typically 20 C to 25 C, with excursions permitted up to 30 C.

Storage Constraint	Requirement
Environment	Protect from moisture; the oral suspension must also be protected from light.
Packaging	Keep in the original container and ensure the cap or lid is tightly closed.
Safety	Store the medicine securely, out of the sight and reach of children.

For disposal, official guidelines recommend using a community drug take-back program. If a program is unavailable, unused medication should be mixed with an undesirable substance, sealed in a container, and discarded in household trash; the medicine must not be flushed down the toilet.